CTIS2022-501176-26-00招募中1 期
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack - 70033093STR3001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age =40 years of age, Ischemic Stroke: a neurological deficit attributable to an acute brain infarction and NIHSS score = 7 and at least 1 of the following: Persistent signs or symptoms of the ischemic event at the time of randomization, OR Acute, ischemic brain lesion determined by standard-of-care neuroimaging OR Participant underwent thrombolysis or thrombectomy OR TIA: acute onset neurological deficit attributable to focal ischemia of the brain by history or examination, with complete symptom resolution of the deficit and no brain infarction on neuroimaging (eg, CT scan or MRI, performed as part of standard medical practice), and ABCD2 Score =6, Participants will be randomized as soon as possible after determining eligibility and within 48 hours of onset of event. In participants in whom a stroke was evident on awakening from sleep, within 48 hours from the time at which the participants’ condition was last reported to be normal. Participants who received thrombolysis and/or mechanical thrombectomy with or without stenting can be randomized but only after 24 hours have elapsed after the end of this treatment and not more than 48 hours after the onset of the index event, and provided that post-treatment neuroimaging excludes cerebral bleeding and have postthrombolytic therapy/post-thrombectomy INR = 1.5 and aPTT = 1.4 times the ULN prior to study randomization. Cerebrovascular vessel stenting is allowed as clinically indicated. If these procedures are done pre-randomization, then randomization should occur at least 24 hours after the end of the procedure and not more than 48 hours after the onset of the index event., Current or planned antiplatelet treatment per international and/or local guidelines. If ASA is used, it will be limited to low dose (75 to 100 mg/day). Loading dose of antiplatelet agents (including ASA) are allowed per standard-of-care, A female participant must be a. Not of childbearing potential or b. Of childbearing potential and practicing a highly effective method of contraception (failure rate of <1% per year when used consistently and correctly) and agrees to remain on a highly effective method until 4 days (5 half lives) after last dose of study intervention –the end of relevant exposure. The investigator must evaluate the potential for contraceptive method failure (eg, noncompliance, recently initiated) in relationship to the first dose of study intervention.
排除标准
- •Current intracranial hemorrhage (hemorrhage into the brain, subarachnoid hemorrhage, intraventricular hemorrhage, subdural hematoma or epidural hematoma); except CMB and minor hemorrhagic transformation of infarct manifesting as scattered petechiae (Hemorrhagic Infarction Type 1 [HI1] according to Heidelberg classification)., Prior history of intracranial hemorrhage except subarachnoid hemorrhage > 1 year prior with adequate treatment., The index stroke or TIA is considered to have a cardio-embolic etiology based on local standard-of-care investigations and for which guidelines recommend anticoagulation., The index stroke or TIA considered to have an other known cause, not related to athero-thrombotic sources (TOAST Other Determined Etiology) based on local standard-of-care investigations. Examples of such etiologies include intracranial tumor, arteritis, arterial dissection, vasospasm or AVM., Pre-event disability with mRS score of 3 or higher., Any condition that requires chronic anticoagulation at the discretion of the investigator and/or local guidelines. Note: Participants with an indication for chronic antiplatelet therapy after placement of a bio-prosthetic nonmechanical valve (eg, transcatheter aortic valve replacement [TAVR]) do not satisfy this exclusion criterion and are eligible for study participation, Conditions with an increased risk of bleeding, including: Clinically significant bleeding within the previous 3 months Known bleeding diathesis Known aPTT prolongation > 1.4 times the ULN or known congenital FXI deficiency Spinal cord hemorrhage Retinal hemorrhage, eGFR <15 mL/min/1.73 m2 at screening, Any of the following laboratory results, based on local laboratory, outside of the ranges specified below prior to randomization: ALT ? 3X ULN Platelet count <75,000 mm3 Total bilirubin = 1.5x ULN unless an alternative causative factor such as Gilbert’s syndrome is identified Hemoglobin <8.0 g/d
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus - N/AEUCTR2004-002902-31-SKTheravance, Inc.746
尚未招募
3 期
A Study of Milvexian in Participants after an Acute Ischemic Stroke or High-Risk Transient Ischemic AttackCTRI/2023/10/058359Janssen Research & Development, LLC
进行中（未招募）
1 期
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous UrticariaEUCTR2022-001745-20-LTCuraTeQ Biologics Private Ltd.600
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus - N/AHospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureusMedDRA version: 8.1Level: LLTClassification code 10052596Term: Nosocomial pneumoniaEUCTR2004-002902-31-GBTheravance, Inc.746
招募中
3 期
A Study of Milvexian in Participants after an Acute Ischemic Stroke or High-Risk Transient Ischemic AttackIschemic StrokeIschemic Attack, TransientJPRN-jRCT2031230040akano Masayoshi15,000